These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16097885)

  • 21. Structural genomics in the biotechnology sector.
    Dry S; McCarthy S; Harris T
    Nat Struct Biol; 2000 Nov; 7 Suppl():946-9. PubMed ID: 11103995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of G protein-coupled receptors as targets in drug discovery.
    Lundstrom K
    IDrugs; 2005 Nov; 8(11):909-13. PubMed ID: 16254784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Doing more than just the structure-structural genomics in kinase drug discovery.
    Marsden BD; Knapp S
    Curr Opin Chem Biol; 2008 Feb; 12(1):40-5. PubMed ID: 18267130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yeast genomics and proteomics in drug discovery and target validation.
    Parsons AB; Geyer R; Hughes TR; Boone C
    Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based approaches to antibiotic drug discovery.
    Nicola G; Abagyan R
    Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.2. PubMed ID: 19235149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural genomics and drug discovery: all in the family.
    Weigelt J; McBroom-Cerajewski LD; Schapira M; Zhao Y; Arrowsmith CH
    Curr Opin Chem Biol; 2008 Feb; 12(1):32-9. PubMed ID: 18282486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent applications of protein crystallography and structure-guided drug design.
    Williams SP; Kuyper LF; Pearce KH
    Curr Opin Chem Biol; 2005 Aug; 9(4):371-80. PubMed ID: 16006182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher-throughput approaches to crystallization and crystal structure determination.
    Fogg MJ; Wilkinson AJ
    Biochem Soc Trans; 2008 Aug; 36(Pt 4):771-5. PubMed ID: 18631156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein models in drug discovery.
    Norin M; Sundström M
    Curr Opin Drug Discov Devel; 2001 May; 4(3):284-90. PubMed ID: 11560059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role and challenges of proteomics in pharma and biotech: technical, scientific and commercial perspective.
    Qoronfleh MW
    Expert Rev Proteomics; 2006 Apr; 3(2):179-95. PubMed ID: 16608432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docking and scoring protein complexes: CAPRI 3rd Edition.
    Lensink MF; Méndez R; Wodak SJ
    Proteins; 2007 Dec; 69(4):704-18. PubMed ID: 17918726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput crystallography for lead discovery in drug design.
    Blundell TL; Jhoti H; Abell C
    Nat Rev Drug Discov; 2002 Jan; 1(1):45-54. PubMed ID: 12119609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-hybrid technologies in proteomics research.
    Suter B; Kittanakom S; Stagljar I
    Curr Opin Biotechnol; 2008 Aug; 19(4):316-23. PubMed ID: 18619540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LigEvolutioner, a new strategy for modification and optimization of lead compounds in receptor/ligand complexes.
    Zhou P; Tian F; Shang Z
    Chem Biol Drug Des; 2008 Dec; 72(6):525-32. PubMed ID: 19090919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions.
    Huber W
    J Mol Recognit; 2005; 18(4):273-81. PubMed ID: 15997470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of the pipeline for structural and functional characterization of macrophage proteins at the university of queensland.
    Meng W; Forwood JK; Guncar G; Robin G; Cowieson NP; Listwan P; Mouradov D; King G; Ross IL; Robinson J; Puri M; Hill JM; Kellie S; Huber T; Hume DA; Martin JL; Kobe B
    Methods Mol Biol; 2008; 426():577-87. PubMed ID: 18542891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NMR screening for rapid protein characterization in structural proteomics.
    Hill JM
    Methods Mol Biol; 2008; 426():437-46. PubMed ID: 18542882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.
    Erlanson DA; Hansen SK
    Curr Opin Chem Biol; 2004 Aug; 8(4):399-406. PubMed ID: 15288250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.